Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Related Posts
Torgersen J, Newcomb CW, Skanderson M, Kidwai-Khan F, Carbonari DM, Tate JP, Mezzacappa C, Cartwright EJ, Bhattacharya D, Lim JK, Price JC, Taddei TH, Justice[...]
Delaney JA, Drumright LN, Newcomb ME, Milloy MJ, Smith MS, Mandler R, Swenson B, Fahey CA, DeBeck K, Metha S, Genberg BL, Mustanski B, Whitney[...]
Mutwadi Malembe A, Nkamba Mukadi D, Hoff NA, Merritt S, Halbrook M, Mafuta Musalu E, Kasonga Ngindu JB, Babakazo P, Mandja Makasa BA, Kanyinda Kayembe[...]